NXG Share Price | NexgenRx, Inc. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare NexgenRx, Inc. with Similar Stocks

TDG Gold Corp.Personas Social, Inc.American Aires, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 17.21%

Company has a low Debt to Equity ratio (avg) at times

With a growth in Net Profit of 295.22%, the company declared Very Positive results in Sep 25

With ROE of 17.41%, it has a expensive valuation with a 3.09 Price to Book Value

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

CAD 26 Million (Micro Cap)

P/E

18.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-3.92

Return on Equity

17.41%

Price to Book

3.09

Revenue and Profits:

Net Sales:

4 Million

(Quarterly Results - Sep 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-8.11%

6 Months

-12.82%

1 Year

36.0%

2 Years

61.9%

3 Years

21.43%

4 Years

0.0%

5 Years

25.93%

NexgenRx, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

10.70%

EBIT Growth (5y)

-0.20%

EBIT to Interest (avg)

0.73

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-3.16

Sales to Capital Employed (avg)

1.82

Tax Ratio

37.71%

Dividend Payout Ratio

169.49%

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

17.21%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.09

EV to EBIT

-6.93

EV to EBITDA

-3.19

EV to Capital Employed

0.29

EV to Sales

-0.42

PEG Ratio

0.04

Dividend Yield

ROCE (Latest)

-3.74%

ROE (Latest)

17.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 5.00% vs 25.00% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 500.00% vs 200.00% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.20",
          "val2": "4.00",
          "chgp": "5.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.50",
          "val2": "0.30",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.60",
          "val2": "0.10",
          "chgp": "500.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.50%",
          "val2": "6.10%",
          "chgp": "4.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 19.55% vs 5.56% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 300.00% vs 0.00% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.90",
          "val2": "13.30",
          "chgp": "19.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.90",
          "val2": "0.60",
          "chgp": "216.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.60",
          "val2": "-0.30",
          "chgp": "300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.00%",
          "val2": "-52.90%",
          "chgp": "9.19%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

4.20

4.00

5.00%

Operating Profit (PBDIT) excl Other Income

0.50

0.30

66.67%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.60

0.10

500.00%

Operating Profit Margin (Excl OI)

46.50%

6.10%

4.04%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 5.00% vs 25.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 500.00% vs 200.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

15.90

13.30

19.55%

Operating Profit (PBDIT) excl Other Income

1.90

0.60

216.67%

Interest

0.20

Exceptional Items

0.00

Consolidate Net Profit

0.60

-0.30

300.00%

Operating Profit Margin (Excl OI)

39.00%

-52.90%

9.19%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 19.55% vs 5.56% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 300.00% vs 0.00% in Dec 2023

All Annual Results

Company CV

About NexgenRx, Inc.

NexgenRx, Inc.

Miscellaneous

NexgenRx Inc. (NexgenRx) administers, adjudicates and pays drug, dental and other extended healthcare claims for the beneficiaries of health benefit plans underwritten by its customers, using computer software. The Company is engaged in the sale of its administration and health benefit claims adjudication services to organizations managing health benefit plans on behalf of plan sponsors, such as employers and associations, among others, and to the Canadian plan sponsors providing an Administrative Services Only (ASO) health benefit plan to their plan members. The health benefit claims include drug, dental, extended health and healthcare spending account claims. The Company sells its service on a fee-per-transaction basis, in addition to per member administration fees. The Company's Web-based product, theclaimsXchange.com, offers a platform, which allows various extended health providers to submit claims on behalf of their patients for benefits through a Web portal.

Company Coordinates

Company Details

185 The West Mall, Suite 600 , TORONTO CA : M9C 5L5

Tel: 1 416 69533931 416 6953393

http://www.nexgenrx.com/

Registrar Details